NovoCure Analyst Price Targets - Benzinga

NovoCure Ltd

NVCRNASDAQ

Trade with Public

Trade with Public

$14.30

-0.42-2.85%

마지막 업데이트: Oct 14, 8:30 AM

$14.40

-0.32-2.17%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

NovoCure Analyst Price Targets - Benzinga

NovoCure Analyst Price Targets

Wall Street analyst price targets and consensus rating for NovoCure (NVCR).

Price Target Range — 11 Quarters

Analyst Consensus — 6 Analysts

4Buy

2Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$27Upside to Avg. PT+88.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 24, 2026	Wedbush	David Nierengarten	PT Raise	Neutral	$18→$20
Jul 23, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$46→$52
Jul 13, 2026	JP Morgan	Jessica Fye	Reinstates	Neutral	$17
Jun 18, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$48→$46
May 4, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$14→$17
May 1, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$16→$20
Apr 16, 2026	Wedbush	David Nierengarten	Maintained	Neutral	$18
Feb 26, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$47→$49
Feb 12, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$39→$47
Jan 15, 2026	Wedbush	David Nierengarten	Maintained	Neutral	$18
Jan 13, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$42→$39
Oct 30, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$38→$42
Oct 27, 2025	JP Morgan	Jessica Fye	PT Cut	Neutral	$25→$23
Jul 25, 2025	Wells Fargo	Larry Biegelsen	Downgrade	Overweight→Equal-Weight	$40→$15
Jul 8, 2025	Ladenburg Thalmann	Kevin DeGeeter	Initiate	Buy	$30
Jun 27, 2025	Piper Sandler	Jason Bednar	Maintained	Overweight	$34
Apr 23, 2025	Piper Sandler	Jason Bednar	PT Cut	Overweight	$42→$34
Apr 16, 2025	Wedbush	David Nierengarten	PT Cut	Neutral	$29→$27
Apr 10, 2025	JP Morgan	Jessica Fye	PT Cut	Neutral	$29→$28
Jan 14, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$38

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20

Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $18 to $20.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52

HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $46 to $52.

Benzinga Newsdesk

PRO
JP Morgan Reinstates Neutral on NovoCure, Announces $17 Price Target

JP Morgan analyst Jessica Fye reinstates NovoCure (NASDAQ:NVCR) with a Neutral and announces $17 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NovoCure, Lowers Price Target to $46

HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Buy and lowers the price target from $48 to $46.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on NovoCure, Raises Price Target to $17

Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Equal-Weight and raises the price target from $13.5 to $17.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on NovoCure, Raises Price Target to $20

Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and raises the price target from $16 to $20.

Benzinga Newsdesk